← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Agenebio, Inc.
Baltimore, MD
$40,280,100
Total funding
7
Grants
Funding over time
peak $11.1M · FY2012–25$20M$15M$10M$5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,280,100 · 7
By mechanism
R01$24,186,020 · 1
U01$7,220,724 · 2
R56$4,000,000 · 1
R44$3,229,045 · 1
UH3$992,883 · 1
UH2$651,428 · 1
Investigators at Agenebio, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,951,060
R01 · FY2018 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,948,571
R01 · FY2019 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,942,354
R01 · FY2020 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$4,903,985
R01 · FY2020 · AG
A Phase 3 pivotal trial of AGB101 to slow progression in MCI due to Alzheimer's Disease$4,000,000
R56 · FY2017 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$2,844,834
R01 · FY2021 · AG
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease$1,595,216
R01 · FY2022 · AG
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$1,249,115
R44 · FY2020 · AG
Structurally Diverse GABA-A ÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD$1,118,843
R44 · FY2019 · AG
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2023 · AG
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2022 · AG
Preclinical and early clinical development of a GABA-A a5 PAM$1,100,000
U01 · FY2024 · AG
Preclinical and early clinical development of a GABA-A a5 PAM$1,078,000
U01 · FY2025 · AG
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$651,678
UH3 · FY2018 · NS
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD$651,428
UH2 · FY2017 · NS
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD$625,713
R44 · FY2021 · AG
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$424,363
U01 · FY2016 · AG
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$424,363
U01 · FY2014 · AG
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$423,822
U01 · FY2012 · AG
GABA-A alpha-5 agonists for the treatment of amnestic Mild Cognitive Impairment$400,517
U01 · FY2013 · AG